Vanguard Capital Management
QNCX icon

Vanguard Capital Management’s Quince Therapeutics QNCX Stock Holding History

Vanguard Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
12,044
+9,737
+422% +$224K ﹤0.01% 3814
2026
Q1 		$46.6K Buy
+2,307
New +$463K ﹤0.01% 3924

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management's QNCX Position: Q2 2026 in Review

Vanguard Capital Management increased its Quince Therapeutics (QNCX) stake by 422% in Q2 2026, buying an estimated $224K and bringing the position to 12,044 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #3814.

Vanguard Capital Management first reported a position in QNCX in Q1 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Vanguard Capital Management held 12,044 shares of Quince Therapeutics worth $219K as of Q2 2026.
  • Vanguard Capital Management bought 9,737 Quince Therapeutics shares in Q2 2026, an estimated $224K.
  • Quince Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3814 holding.
  • Vanguard Capital Management first reported a position in Quince Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 25 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.